阿替普酶静脉溶栓治疗急性缺血性脑卒中患者的临床观察
2018-04-26招树涛甘智涛黄丽霜黄玉琪
招树涛 甘智涛 黄丽霜 黄玉琪
[摘要]目的 观察阿替普酶静脉溶栓治疗急性缺血性脑卒中的临床效果。方法 收集本院2015年4月~2017年5月收治的92例ASI患者,根据在溶栓时间窗内是否溶栓,分观察组(n=47)和对照组(n=45),分别予以阿替普酶静脉溶栓治疗、常规治疗。比较两组的治疗效果、NIHSS评分、不良事件发生率。结果 观察组的总有效率为93.6%,显著高于对照组(77.8%)(χ2=4.7533,P=0.0292)。观察组溶栓2 h、24 h、14 d、3个月的NIHSS评分均低于对照组(P<0.05)。观察组的不良事件总发生率为4.3%,低于对照组的22.2%(χ2=6.5429,P<0.05)。结论 阿替普酶静脉溶栓治疗急性缺血性脑卒中可有效减缓患者的神经功能缺损程度,减少不良事件,改善预后,临床效果显著,值得借鉴。
[关键词]阿替普酶静脉溶栓;急性缺血性脑卒中;临床效果
[中图分类号] R743.3 [文献标识码] A [文章编号] 1674-4721(2018)2(a)-0067-03
[Abstract]Objective To observe the clinical effect of intravenous thrombolysis with Alteplase in the treatment of acute ischemic stroke.Methods A total of 92 patients with acute ischemic stroke admitted into our hospital from April 2015 to May 2017 were collected.The patients were divided into the observation group (n=47) and the control group (n=45) according to whether they were thrombolyzed in the thrombolytic time window.Intravenous thrombolysis with Alteplase and routine treatment was given respectively.The curative effect,NIHSS score and incidence rate of adverse events were compared between the two groups.Results The total effective rate of the observation group was 93.6%,which was significantly higher than that of the control group (77.8%) (χ2=4.7533,P=0.0292).The scores of 2 h,24 h,14 d and 3 months of thrombolysis in the observation group were lower than those in the control group (P<0.05).The total incidence of adverse events in the observation group was 4.3%,which was lower than that of the control group (22.2% ) (χ2=6.5429,P<0.05).Conclusion Intravenous thrombolysis treatment of Alteplase can effectively reduce the degree of neurological deficit in the patients with acute ischemic stroke,reduce the incidence of adverse events and improve prognosis.The clinical effect is significant,which is worthy of reference.
[Key words]Intravenous thrombolysis;Acute ischemic stroke;Clinical effect
脑卒中是一种临床常见病,其中最常见的类型就是急性缺血性脑卒中(acute ischemic stroke,ASI),该病的病死率极高,即便存活的患者也会留下不同程度的功能障碍,因此临床治疗应将重点放在改善功能障碍、提升生活能力方面[1]。阿替普酶是当前临床治疗ASI的一种常用药物。本文探讨ASI患者在早期应用阿替普酶静脉溶栓治疗的效果,现报道如下。
1资料与方法
1.1一般资料
收集本院2015年4月~2017年5月收治的92例ASI患者,将其分为观察组(n=47)和对照组(n=45)。观察组男女比例30∶17;年龄为38~74岁,平均(56.05±17.62)岁;发病时间为1~6 h,平均(3.52±2.62)h。对照组男女比例26∶19;年龄为40~70岁,平均(55.06±15.82)岁;发病时间为2~6 h,平均(4.06±2.07)h。两组患者的一般资料差异无统计学意义(P>0.05),具有可比性。
1.2 纳入标准
①MRI、CT均已確诊为ASI;②得到伦理委员会批准;③研究前,患者、家属均知情,并签署《知情同意书》;④年龄≤80周岁。
1.3 排除标准
①肝、肾、心、肺等脏器合并重大疾病者;②临床资料不齐全的;③合并肿瘤、心力衰竭等重大疾病者;④对本研究涉及药物过敏者;……
